查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088666

緩釋藥物遞送市場：按類型、技術、藥物類型、給藥途徑、製劑類型、應用和最終用戶分類－2026-2032年全球市場預測

Controlled Release Drug Delivery Market by Type, Technology, Drug Type, Route of Administration, Formulation Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，緩釋藥物輸送市場將成長至 1,367.4 億美元，複合年成長率為 10.90%。

主要市場統計數據
基準年 2025 662.5億美元
預計年份：2026年 729.4億美元
預測年份 2032 1367.4億美元
複合年成長率 (%) 10.90%

緩釋藥物遞送技術正從製劑優勢轉向核心商業策略，涵蓋注射劑、口服固體製劑、植入、經皮系統、眼內植入劑和吸入平台。該領域以聚合物基質、滲透泵、脂質體、微球、水凝膠、脂質奈米顆粒和生物可分解儲庫等成熟科學為基礎，並在腫瘤學、糖尿病、思覺失調症、避孕、疼痛管理、眼科學和感染疾病領域擁有監管先例。

這種需求源於可衡量的醫療優先事項，例如減少給藥頻率、提高遵守用藥性、最大限度地降低峰谷毒性以及延長產品在獨家銷售期後的生命週期。用於 HIV 預防的長效注射劑、每週一次的 GLP-1長效型、長效抗精神病藥物、緩釋眼科藥物和長效避孕藥表明，緩釋平台可以提高治療的一致性，同時支持差異化的臨床和商業性定位。

緩釋技術領域的變革性變化

緩釋藥物遞送領域正從傳統的緩釋片劑轉向以病人為中心的高價值系統，這些系統融合了藥物、醫療設備、材料科學和數位監測技術。複雜的注射劑、可生物分解的植入、奈米顆粒載體、經皮吸收貼片和防濫用口服製劑正日益受到關注，因為它們能夠解決速釋產品通常無法解決的用藥依從性、安全性和易用性等問題。

人工智慧（AI）的累積影響

人工智慧正日益成為緩釋藥物遞送領域的重要驅動力，尤其是在製劑篩檢、聚合物選擇、釋放動力學建模、輔料適用性以及放大生產過程中的風險控制等方面。機器學習模型能夠透過評估歷史輔料行為、粒徑分佈、溶出曲線、流變學特性、分解途徑和穩定性等資料集，縮短實驗室迭代週期，並識別出技術成功機率較高的製劑候選方案。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

隨著中國、印度、日本、韓國和澳洲不斷提升其在複雜學名藥、特殊注射劑、生物製藥和先進材料領域的交付能力，亞太地區正成為重要的成長引擎。中國國家藥品監督管理局正在加強對創新和複雜製劑的核准流程，而印度龐大的學名藥生產規模則為具有成本緩釋片片劑、膠囊、注射劑和合約開發提供了支持。日本和韓國擁有先進的聚合物科學、醫療設備整合、高品質的臨床開發基礎設施和精密製造能力，而澳洲則在臨床評估和產品引入受監管的醫療保健領域方面繼續發揮著至關重要的作用。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協市場，慢性病負擔日益加重、全民健康覆蓋（UHC）計畫的擴展，以及新加坡、馬來西亞、泰國、印尼、越南和菲律賓等國製藥業的成長，都進一步提升了緩釋製劑的重要性。海灣合作理事會（GCC）國家已將醫療保健產業的多元化列為戰略重點，這催生了對特種製劑、長效注射劑、無菌生產以及符合其國家產業戰略的本地化藥品生產的需求。

對主要緩釋製劑市場關鍵國家的洞察

美國憑藉FDA在複雜學名藥、複方製劑、長效注射劑、防濫用製劑和先進製造項目的經驗，在緩釋藥物的商業化方面處於領先地位。同時，加拿大強調基於證據的報銷機制以及對安全性、品質和療效的高標準。墨西哥和巴西是拉丁美洲的重要市場，它們擴大了專科藥物的可及性，加強了監管能力，並支持國內製藥能力發展，以應對慢性病和公共衛生需求。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠解決可衡量的臨床問題的製劑平台，而不是簡單地延長給藥間隔。最大的機會在於那些藥物依從性、毒性、給藥負擔、局部給藥或療效差異對治療結果有重大影響的治療領域，例如糖尿病、癌症支持治療、精神健康、眼科、避孕、愛滋病預防和慢性疼痛。

調查方法

本執行摘要基於二手研究，參考了監管指南、已通過核准產品先例、同行評審的藥學文獻、公共衛生資訊來源、臨床應用趨勢以及檢驗的行業文件。分析重點關注循證指標，例如FDA和EMA對複雜產品的期望、長效注射劑的徵兆記錄以及針對無菌、聚合物、奈米顆粒、經皮、植入和複雜產品系統的既定生產要求。

結論

緩釋藥物遞送技術正成為現代製藥的關鍵特徵，它將治療效果與患者的便利性、依從性、安全性以及產品差異化聯繫起來。該領域不再局限於緩釋片，現在還包括長效注射劑、植入、奈米顆粒、脂質體、緩釋製劑、經皮給藥平台、眼用植入劑、吸入系統以及藥物與醫療設備的組合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：緩釋藥物遞送市場：依類型分類

  • 化學控制
    • 離子泳
    • pH響應性
    • 質子化
  • 擴散控制型
  • 溶解控制型
  • 滲透壓法
  • 刺激誘發
    • 磁的
    • 溫度
    • 超音波

第8章：緩釋藥物遞送市場：依技術分類

  • 脂質體
    • 傳統的
    • 配體標靶
    • 聚乙二醇化
  • 微膠囊化
    • 核心鋸齒
    • 溶劑蒸發法
    • 噴霧乾燥
  • 微球
    • 幾丁聚醣
    • 明膠
    • PLGA
  • 奈米顆粒
    • 樹狀聚合物
    • 無機物
    • 脂質系統
    • 聚合物體系

第9章：緩釋藥物遞送市場：依藥物類型分類

  • 生物製劑
    • 單株抗體
    • 胜肽
    • 蛋白質
    • 疫苗
  • 低分子

第10章：緩釋藥物遞送市場：依給藥途徑分類

  • 口服
  • 腸外
  • 經皮
  • 眼科

第11章：緩釋藥物遞送市場：依製劑類型分類

  • 固體的
    • 藥片
    • 膠囊
    • 植入
  • 半固態製劑
  • 液體

第12章 緩釋藥物遞送市場：依應用領域分類

  • 心血管系統
    • 高血壓
    • 抗血栓藥物
  • 中樞神經系統疾病
  • 感染疾病
  • 腫瘤學
    • 荷爾蒙剝奪療法
    • 標靶化療儲存庫
  • 疼痛管理

第13章：緩釋藥物遞送市場：依最終用戶分類

  • 診所
  • 家庭醫療保健
  • 醫院
  • 專業醫療中心
  • 研究和學術機構

第14章：緩釋藥物遞送市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：緩釋藥物遞送市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：緩釋藥物遞送市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Bayer AG
  • Becton Dickinson and Company
  • Boston Scientific Corporation
  • Catalent Inc.
  • Cipla Limited
  • Dr Reddys Laboratories Ltd.
  • Eli Lilly and Company
  • Evonik Industries AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lonza Group AG
  • Lupin Limited
  • Medtronic plc
  • Merck & Co Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd/
  • Viatris Inc.
Product Code: MRR-A339DAEFA6EE

The Controlled Release Drug Delivery Market is projected to grow by USD 136.74 billion at a CAGR of 10.90% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 66.25 billion
Estimated Year [2026] USD 72.94 billion
Forecast Year [2032] USD 136.74 billion
CAGR (%) 10.90%

Controlled release drug delivery is moving from a formulation advantage to a core commercial strategy across injectables, oral solid dosage forms, implants, transdermal systems, ophthalmic inserts, and inhalable platforms. The field is supported by established science in polymer matrices, osmotic pumps, liposomes, microspheres, hydrogels, lipid nanoparticles, and biodegradable depots, with regulatory precedent across oncology, diabetes, schizophrenia, contraception, pain management, ophthalmology, and infectious disease.

Demand is reinforced by measurable healthcare priorities: reducing dosing frequency, improving medication adherence, minimizing peak-to-trough toxicity, and extending product lifecycles after loss of exclusivity. Long-acting injectables for HIV prevention, weekly GLP-1 therapies, depot antipsychotics, sustained-release ophthalmic therapies, and long-acting contraceptives demonstrate how controlled release platforms can improve therapeutic consistency while supporting differentiated clinical and commercial positioning.

Transformative Shifts in the Controlled Release Landscape

The controlled release drug delivery landscape is shifting from conventional sustained-release tablets toward high-value, patient-centric systems that combine drug, device, material science, and digital monitoring. Complex injectables, biodegradable implants, nanoparticle carriers, transdermal patches, and abuse-deterrent oral formulations are gaining attention because they address adherence, safety, and usability challenges that immediate-release products often cannot solve.

Another major shift is the rise of lifecycle management through formulation innovation. As biologics, peptides, nucleic acid therapeutics, and highly potent compounds become more common, developers are investing in technologies that protect unstable active ingredients, enable localized release, and reduce administration burden. Regulatory agencies are also emphasizing quality-by-design, in vitro-in vivo correlation, comparative product performance, and robust manufacturing controls, making development discipline as important as platform novelty.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator for controlled release drug delivery, particularly in formulation screening, polymer selection, release-kinetic modeling, excipient compatibility, and scale-up risk reduction. Machine learning models can evaluate historical excipient behavior, particle-size distributions, dissolution profiles, rheology, degradation pathways, and stability datasets to shorten iterative laboratory cycles and identify formulation candidates with a higher probability of technical success.

AI also strengthens quality and regulatory readiness. Predictive analytics applied to process analytical technology, continuous manufacturing, and real-time release testing can detect deviations earlier and support more consistent batch performance. In clinical development, pharmacokinetic modeling, digital twins, and AI-enabled patient stratification can improve dose selection and help demonstrate how controlled release products reduce variability, dosing burden, and adherence gaps in real-world use.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is becoming a major growth engine as China, India, Japan, South Korea, and Australia expand complex generics, specialty injectables, biologics delivery, and advanced materials capabilities. China's National Medical Products Administration has strengthened pathways for innovative and complex formulations, while India's scale in generic manufacturing supports cost-competitive controlled release tablets, capsules, injectables, and contract development. Japan and South Korea contribute advanced polymer science, device integration, high-quality clinical development infrastructure, and precision manufacturing capacity, while Australia remains relevant for clinical evaluation and regulated healthcare adoption.

North America remains the benchmark for premium controlled release innovation due to strong FDA precedent, large specialty pharmaceutical demand, established reimbursement pathways, and early adoption of long-acting therapies across chronic and complex conditions. Europe benefits from harmonized European Medicines Agency oversight, sophisticated health technology assessment, and strong polymer, device, and pharmaceutical engineering capabilities. Latin America, led by Brazil and Mexico, is advancing through chronic disease demand and expanding access to long-acting contraceptives, diabetes therapies, and pain-management products. The Middle East is investing in healthcare modernization, pharmaceutical localization, and specialty medicine access, while Africa's opportunities are linked to long-acting infectious disease, contraception, and adherence-focused therapies where simplified administration and less frequent dosing can improve public health outcomes.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are increasingly relevant for controlled release drug delivery because of rising chronic disease burden, expanding universal health coverage programs, and pharmaceutical manufacturing growth in Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines. The GCC is positioning healthcare diversification as a strategic priority, creating demand for specialty formulations, long-acting injectables, sterile manufacturing, and localized pharmaceutical production aligned with national industrial strategies.

The European Union provides one of the strongest regulatory and commercialization environments for complex delivery systems, supported by EMA scientific guidance, advanced clinical networks, pharmacovigilance systems, and sustainability expectations for packaging and devices. BRICS countries combine large patient populations with growing pharmaceutical self-reliance, making them important for scale, affordability, local manufacturing, and complex generic development. G7 countries drive premium innovation, intellectual property creation, regulatory science, and clinical adoption, while NATO-aligned markets benefit from resilient supply-chain initiatives that increasingly include essential medicines, sterile injectables, combination products, and critical delivery technologies.

Key Country Insights Across Major Controlled Release Markets

The United States leads in controlled release drug delivery commercialization through FDA experience with complex generics, combination products, long-acting injectables, abuse-deterrent formulations, and advanced manufacturing programs, while Canada emphasizes evidence-based reimbursement and high standards for safety, quality, and therapeutic value. Mexico and Brazil are important Latin American markets as they expand specialty medicine access, strengthen regulatory capacity, and support domestic pharmaceutical capabilities for chronic disease and public health needs.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature clinical systems with growing interest in adherence-improving therapies, specialty injectables, and drug-device combinations, while Russia maintains demand for localized production, essential medicines, and cost-effective controlled release options. China is scaling innovation and manufacturing for complex formulations, India remains a global force in controlled release generics and contract manufacturing, Japan is recognized for high-quality drug-device development and patient-centric formulation design, Australia supports advanced clinical evaluation and regulated adoption, and South Korea is strengthening its position in biologics, injectables, smart delivery systems, and precision drug delivery technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize formulation platforms that solve measurable clinical problems, not only extend dosing intervals. The strongest opportunities are in therapies where adherence, toxicity, administration burden, local delivery, or therapeutic variability materially affects outcomes, including diabetes, oncology supportive care, psychiatric disorders, ophthalmology, contraception, HIV prevention, and chronic pain.

Companies should invest early in quality-by-design, scalable manufacturing, device usability, extractables and leachables testing, container-closure integrity, sterilization strategy, and human factors engineering. Strategic partnerships with CDMOs, polymer specialists, device manufacturers, clinical pharmacology experts, and AI-enabled modeling providers can reduce development risk. Commercial teams should also generate real-world evidence showing fewer clinic visits, improved persistence, lower complication rates, better patient experience, or reduced total cost of care.

Research Methodology

This executive summary is structured around secondary research from regulatory guidance, approved-product precedents, peer-reviewed pharmaceutics literature, public health sources, healthcare adoption trends, and validated industry documentation. The analysis emphasizes evidence-backed signals such as FDA and EMA expectations for complex products, documented use of long-acting injectables, and established manufacturing requirements for sterile, polymeric, nanoparticle, transdermal, implantable, and combination-product systems.

Insights are synthesized using a market-intelligence framework that evaluates technology readiness, therapeutic relevance, manufacturing scalability, regulatory complexity, regional adoption capacity, patient access dynamics, and competitive differentiation. The methodology avoids unsupported market-size, market-share, and forecasting claims, focusing instead on verified drivers, constraints, and strategic implications for controlled release drug delivery stakeholders.

Conclusion

Controlled release drug delivery is becoming a defining capability in modern pharmaceuticals because it links therapeutic performance with patient convenience, adherence, safety, and product differentiation. The category is no longer limited to extended-release tablets; it now includes long-acting injectables, implants, nanoparticles, liposomes, depots, transdermal platforms, ophthalmic inserts, inhalable systems, and drug-device combinations.

The next phase of industry advancement will favor organizations that combine formulation science, AI-enabled development, regulatory discipline, patient-centered design, and scalable manufacturing. Stakeholders that demonstrate clinical value, real-world adherence benefits, dependable quality, and practical access advantages will be best positioned to lead in this increasingly competitive controlled release drug delivery landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Controlled Release Drug Delivery Market, by Type

  • 7.1. Chemically-Controlled
    • 7.1.1. Iontophoresis
    • 7.1.2. pH Sensitive
    • 7.1.3. Protonation
  • 7.2. Diffusion-Controlled
  • 7.3. Dissolution-Controlled
  • 7.4. Osmotic
  • 7.5. Stimuli-Induced
    • 7.5.1. Magnetic
    • 7.5.2. Temperature
    • 7.5.3. Ultrasound

8. Controlled Release Drug Delivery Market, by Technology

  • 8.1. Liposomes
    • 8.1.1. Conventional
    • 8.1.2. Ligand-Targeted
    • 8.1.3. PEGylated
  • 8.2. Microencapsulation
    • 8.2.1. Coacervation
    • 8.2.2. Solvent Evaporation
    • 8.2.3. Spray Drying
  • 8.3. Microspheres
    • 8.3.1. Chitosan
    • 8.3.2. Gelatin
    • 8.3.3. PLGA
  • 8.4. Nanoparticles
    • 8.4.1. Dendrimer
    • 8.4.2. Inorganic
    • 8.4.3. Lipid Based
    • 8.4.4. Polymeric

9. Controlled Release Drug Delivery Market, by Drug Type

  • 9.1. Biologics
    • 9.1.1. Monoclonal Antibodies
    • 9.1.2. Peptides
    • 9.1.3. Proteins
    • 9.1.4. Vaccines
  • 9.2. Small Molecule

10. Controlled Release Drug Delivery Market, by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Transdermal
  • 10.4. Ocular

11. Controlled Release Drug Delivery Market, by Formulation Type

  • 11.1. Solid
    • 11.1.1. Tablets
    • 11.1.2. Capsules
    • 11.1.3. Implants
  • 11.2. Semi-solid
  • 11.3. Liquid

12. Controlled Release Drug Delivery Market, by Application

  • 12.1. Cardiovascular
    • 12.1.1. Hypertension
    • 12.1.2. Antithrombotics
  • 12.2. CNS Disorders
  • 12.3. Infectious Diseases
  • 12.4. Oncology
    • 12.4.1. Hormone Deprivation Therapy
    • 12.4.2. Targeted chemotherapy depots
  • 12.5. Pain Management

13. Controlled Release Drug Delivery Market, by End User

  • 13.1. Clinics
  • 13.2. Home Healthcare
  • 13.3. Hospitals
  • 13.4. Specialty Centers
  • 13.5. Research & Academic Institutes

14. Controlled Release Drug Delivery Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Controlled Release Drug Delivery Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Controlled Release Drug Delivery Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Abbott Laboratories
  • 18.2. AbbVie Inc.
  • 18.3. Amgen Inc
  • 18.4. AstraZeneca PLC
  • 18.5. Aurobindo Pharma Limited
  • 18.6. Baxter International Inc.
  • 18.7. Bayer AG
  • 18.8. Becton Dickinson and Company
  • 18.9. Boston Scientific Corporation
  • 18.10. Catalent Inc.
  • 18.11. Cipla Limited
  • 18.12. Dr Reddys Laboratories Ltd.
  • 18.13. Eli Lilly and Company
  • 18.14. Evonik Industries AG
  • 18.15. GlaxoSmithKline plc
  • 18.16. Johnson & Johnson
  • 18.17. Lonza Group AG
  • 18.18. Lupin Limited
  • 18.19. Medtronic plc
  • 18.20. Merck & Co Inc.
  • 18.21. Novartis AG
  • 18.22. Pfizer Inc.
  • 18.23. Roche Holding AG
  • 18.24. Sanofi SA
  • 18.25. Sun Pharmaceutical Industries Ltd.
  • 18.26. Teva Pharmaceutical Industries Ltd/
  • 18.27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMICALLY-CONTROLLED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMICALLY-CONTROLLED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMICALLY-CONTROLLED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IONTOPHORESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IONTOPHORESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IONTOPHORESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PH SENSITIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PH SENSITIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PH SENSITIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROTONATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROTONATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROTONATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIFFUSION-CONTROLLED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIFFUSION-CONTROLLED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIFFUSION-CONTROLLED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DISSOLUTION-CONTROLLED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DISSOLUTION-CONTROLLED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DISSOLUTION-CONTROLLED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OSMOTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OSMOTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OSMOTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STIMULI-INDUCED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STIMULI-INDUCED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STIMULI-INDUCED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MAGNETIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MAGNETIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MAGNETIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TEMPERATURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TEMPERATURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TEMPERATURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIPOSOMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIPOSOMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIPOSOMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONVENTIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONVENTIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONVENTIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIGAND-TARGETED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIGAND-TARGETED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIGAND-TARGETED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEGYLATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEGYLATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEGYLATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MICROENCAPSULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MICROENCAPSULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MICROENCAPSULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COACERVATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COACERVATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COACERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SOLVENT EVAPORATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SOLVENT EVAPORATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SOLVENT EVAPORATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SPRAY DRYING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SPRAY DRYING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SPRAY DRYING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MICROSPHERES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MICROSPHERES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MICROSPHERES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHITOSAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHITOSAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHITOSAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GELATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GELATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PLGA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PLGA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PLGA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NANOPARTICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NANOPARTICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NANOPARTICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DENDRIMER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DENDRIMER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DENDRIMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INORGANIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INORGANIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INORGANIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LIPID BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIPID BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LIPID BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POLYMERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POLYMERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL POLYMERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SMALL MOLECULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SMALL MOLECULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SMALL MOLECULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL OCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL OCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL OCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SOLID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SOLID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SOLID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL SEMI-SOLID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL SEMI-SOLID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL SEMI-SOLID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ANTITHROMBOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTITHROMBOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ANTITHROMBOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CNS DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CNS DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CNS DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL HORMONE DEPRIVATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL HORMONE DEPRIVATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL HORMONE DEPRIVATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL TARGETED CHEMOTHERAPY DEPOTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL TARGETED CHEMOTHERAPY DEPOTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL TARGETED CHEMOTHERAPY DEPOTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CHEMICALLY-CONTROLLED, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY STIMULI-INDUCED, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROENCAPSULATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROSPHERES, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CHEMICALLY-CONTROLLED, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY STIMULI-INDUCED, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROENCAPSULATION, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROSPHERES, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CHEMICALLY-CONTROLLED, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY STIMULI-INDUCED, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROENCAPSULATION, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROSPHERES, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CHEMICALLY-CONTROLLED, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY STIMULI-INDUCED, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROENCAPSULATION, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROSPHERES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CHEMICALLY-CONTROLLED, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY STIMULI-INDUCED, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROENCAPSULATION, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROSPHERES, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CHEMICALLY-CONTROLLED, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY STIMULI-INDUCED, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROENCAPSULATION, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROSPHERES, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. GLOBAL CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CHEMICALLY-CONTROLLED, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY STIMULI-INDUCED, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROENCAPSULATION, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROSPHERES, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CHEMICALLY-CONTROLLED, 2018-2032 (USD MILLION)
  • TABLE 314. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY STIMULI-INDUCED, 2018-2032 (USD MILLION)
  • TABLE 315. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 317. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROENCAPSULATION, 2018-2032 (USD MILLION)
  • TABLE 318. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROSPHERES, 2018-2032 (USD MILLION)
  • TABLE 319. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 320. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 322. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 323. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 325. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 326. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 327. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 328. GCC CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CHEMICALLY-CONTROLLED, 2018-2032 (USD MILLION)
  • TABLE 332. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY STIMULI-INDUCED, 2018-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 334. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROENCAPSULATION, 2018-2032 (USD MILLION)
  • TABLE 336. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROSPHERES, 2018-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 338. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 340. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 343. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 344. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 345. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 346. EUROPEAN UNION CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 347. BRICS CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 348. BRICS CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. BRICS CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY CHEMICALLY-CONTROLLED, 2018-2032 (USD MILLION)
  • TABLE 350. BRICS CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY STIMULI-INDUCED, 2018-2032 (USD MILLION)
  • TABLE 351. BRICS CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 352. BRICS CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 353. BRICS CONTROLLED RELEASE DRUG DELIVERY MARKET SIZE, BY MICROENC